229 related articles for article (PubMed ID: 29276062)
1. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
Schlütermann D; Skowron MA; Berleth N; Böhler P; Deitersen J; Stuhldreier F; Wallot-Hieke N; Wu W; Peter C; Hoffmann MJ; Niegisch G; Stork B
Urol Oncol; 2018 Apr; 36(4):160.e1-160.e13. PubMed ID: 29276062
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory proteins FIP-gts and chloroquine induce caspase-independent cell death via autophagy for resensitizing cisplatin-resistant urothelial cancer cells.
Hsin IL; Wang SC; Li JR; Ciou TC; Wu CH; Wu HM; Ko JL
Phytomedicine; 2016 Dec; 23(13):1566-1573. PubMed ID: 27823620
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of grade dependent autophagy in urothelial carcinoma increases cell death under nutritional limiting condition and potentiates the cytotoxicity of chemotherapeutic agent.
Ojha R; Singh SK; Bhattacharyya S; Dhanda RS; Rakha A; Mandal AK; Jha V
J Urol; 2014 Jun; 191(6):1889-98. PubMed ID: 24440234
[TBL] [Abstract][Full Text] [Related]
4. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
Höhn A; Krüger K; Skowron MA; Bormann S; Schumacher L; Schulz WA; Hoffmann MJ; Niegisch G; Fritz G
Oncotarget; 2016 Jul; 7(27):41320-41335. PubMed ID: 27191498
[TBL] [Abstract][Full Text] [Related]
5. Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment.
Berning L; Schlütermann D; Friedrich A; Berleth N; Sun Y; Wu W; Mendiburo MJ; Deitersen J; Brass HUC; Skowron MA; Hoffmann MJ; Niegisch G; Pietruszka J; Stork B
Molecules; 2021 Feb; 26(5):. PubMed ID: 33673611
[TBL] [Abstract][Full Text] [Related]
6. The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
Dyshlovoy SA; Madanchi R; Hauschild J; Otte K; Alsdorf WH; Schumacher U; Kalinin VI; Silchenko AS; Avilov SA; Honecker F; Stonik VA; Bokemeyer C; von Amsberg G
BMC Cancer; 2017 Feb; 17(1):93. PubMed ID: 28143426
[TBL] [Abstract][Full Text] [Related]
7. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083
[TBL] [Abstract][Full Text] [Related]
9. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
Li JR; Cheng CL; Yang CR; Ou YC; Wu MJ; Ko JL
Toxicol Lett; 2013 Jul; 220(3):267-76. PubMed ID: 23651616
[TBL] [Abstract][Full Text] [Related]
11. FIP-gts potentiate autophagic cell death against cisplatin-resistant urothelial cancer cells.
Li JR; Cheng CL; Yang WJ; Yang CR; Ou YC; Wu MJ; Ko JL
Anticancer Res; 2014 Jun; 34(6):2973-83. PubMed ID: 24922662
[TBL] [Abstract][Full Text] [Related]
12. Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer.
Chen CH; Changou CA; Hsieh TH; Lee YC; Chu CY; Hsu KC; Wang HC; Lin YC; Lo YN; Liu YR; Liou JP; Yen Y
Clin Cancer Res; 2018 Mar; 24(5):1176-1189. PubMed ID: 29222162
[No Abstract] [Full Text] [Related]
13. Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer.
Lin W; Sun J; Sadahira T; Xu N; Wada K; Liu C; Araki M; Xu A; Watanabe M; Nasu Y; Huang P
Int J Biol Sci; 2021; 17(12):3255-3267. PubMed ID: 34421363
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
15. Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).
Rohde D; Brehmer B; Kapp T; Valdor M; Jakse G
Urol Res; 1998; 26(4):249-57. PubMed ID: 9759998
[TBL] [Abstract][Full Text] [Related]
16. The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition.
Fukuda T; Oda K; Wada-Hiraike O; Sone K; Inaba K; Ikeda Y; Miyasaka A; Kashiyama T; Tanikawa M; Arimoto T; Kuramoto H; Yano T; Kawana K; Osuga Y; Fujii T
Gynecol Oncol; 2015 Jun; 137(3):538-45. PubMed ID: 25842161
[TBL] [Abstract][Full Text] [Related]
17. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
18. Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma.
Zhang H; Liu L; Liu C; Pan J; Lu G; Zhou Z; Chen Z; Qian C
Oncotarget; 2017 May; 8(21):34362-34373. PubMed ID: 28416766
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
